Ozempic drug reduces death risk in diabetic kidney disease patients, study finds.

Novo Nordisk's diabetes drug, Ozempic, has demonstrated a reduction in the risk of death in patients with kidney disease due to diabetes, according to a study published in the New England Journal of Medicine. The research showed that patients who took Ozempic were one-fifth less likely to die from any cause during the study compared to those who took a placebo. The results suggest that the drug could help manage a range of interrelated conditions around obesity and may change the way kidney disease is treated. Ozempic has previously shown a 24% risk reduction in a range of bad health outcomes linked to kidney and heart disease.